Parasite Viability as a Superior Measure of Antimalarial Drug Activity in Humans

Background Artemisinin derivatives are the leading class of antimalarial drugs due to their rapid onset of action and rapid clearance of circulating parasites. The parasite clearance half-life measures the rate of loss of parasites from blood after treatment, and this is currently used to assess antimalarial activity of novel agents and to monitor resistance. However, a number of recent studies have challenged the use of parasite clearance to measure drug activity, arguing that many circulating parasites may be nonviable. Methods Plasmodium falciparum-infected subjects (n = 10) in a malaria volunteer infection study were administered a single dose of artesunate (2 mg/kg). Circulating parasite concentration was assessed by means of quantitative polymerase chain reaction (qPCR). Parasite viability after artesunate administration was estimated by mathematical modeling of the ex vivo growth of parasites collected from subjects. Results We showed that in artemisinin-sensitive infection, viable parasites declined to <0.1% of baseline within 8 hours after artesunate administration, while the total number of circulating parasites measured with quantitative polymerase chain reaction remained unchanged. In artemisinin-resistant infections over the same interval, viable parasites declined to 51.4% (standard error of the mean, 4.6%) of baseline. Conclusions These results demonstrate that in vivo drug activity of artesunate is faster than is indicated by the parasite clearance half-life. The study estimated parasite viability after artesunate administration in a volunteer malaria infection study. Findings revealed that parasite viability declines rapidly compared with total parasite numbers in infected subjects, and they indicate that artesunate activity is faster than previously reported.

Automated summary

This study found that viable parasites in artemisinin-sensitive infections decreased to <0.1% of baseline within 8 hours after artesunate administration, while the total number of circulating parasites measured with quantitative polymerase chain reaction remained unchanged. In artemisinin-resistant infections over the same interval, viable parasites declined to 51.4% of baseline. These results suggest that the in vivo drug activity of artesunate is quicker than previously reported based on parasite clearance half-life.